Results 41 to 50 of about 42,124 (246)

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker   +2 more
core   +1 more source

Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer

Tumor Biology, 2017
This study explored the mechanism underlying long non-coding RNA ROR regulating autophagy on Tamoxifen resistance in breast cancer. Cancer tissues and adjacent normal tissues were collected from 74 breast cancer patients.
Yuehua Li, Baohong Jiang, Hongbo Zhu, Xiaofei Qu, Liqin Zhao, Yeru Tan, Yiling Jiang, Mingchu Liao, Xiaoping Wu   +8 more
doaj   +1 more source

Expression analysis elucidates the roles of Nicastrin, Notch4, and Hes1 in prognosis and endocrine-therapy resistance in ER-positive breast cancer patients

Research in Pharmaceutical Sciences, 2023
Background and purpose: Although some proposed mechanisms responsible for tamoxifen resistance have already been present, further study is needed to determine the mechanisms underlying tamoxifen resistance more clearly.
Arad Boustan, Rosa Jahangiri, Asefeh Dahmardeh Ghalehno, Mahdieh Khorsandi, Fatemeh Mosaffa, Khadijeh Jamialahmadi   +5 more
doaj   +1 more source

Increased STAT1 signaling in endocrine-resistant breast cancer [PDF]

, 2014
Funding: China Scholarship Council, University of Edinburgh, Scottish Funding Council and Breakthrough Breast Cancer.Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully resistant (MCF-
Thomas Jeremy S., Faratian Dana, Huang Rui, Sims Andrew H., Dana Faratian (171110), Simon P. Langdon, Danielle Wilson (550968), David J. Harrison (171106), Jeremy S. Thomas, Dana Faratian, Rui Huang, Wilson Danielle, Harrison David J., David J. Harrison, Danielle Wilson, Simon P Langdon, Thomas, Jeremy S, Sims, Andrew H, Andrew H. Sims (108040), Harrison, David J, Rui Huang (141490), Huang, Rui, Simon P. Langdon (207293), Wilson, Danielle, David J Harrison, Thomas, Jeremy, Langdon Simon P., Faratian, Dana, Andrew H. Sims, Andrew H Sims, Jeremy S Thomas, Jeremy S. Thomas (550969), Langdon, Simon P   +32 more
core   +1 more source

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

Molecular Cancer, 2010
Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2.
Richer Jennifer K, Edgerton Susan M, Spoelstra Nicole S, Das Partha M, Cittelly Diana M, Thor Ann D, Jones Frank E   +6 more
doaj   +1 more source

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

BMC Cancer, 2018
Background Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood.
Wei Li, Ling Xu, Xiaofang Che, Haizhou Li, Ye Zhang, Na Song, Ti Wen, Kezuo Hou, Yi Yang, Lu Zhou, Xing Xin, Lu Xu, Xue Zeng, Sha Shi, Yunpeng Liu, Xiujuan Qu, Yuee Teng   +16 more
doaj   +1 more source

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer

Life, 2022
NCOR2 is a co-repressor for estrogen receptor (ER) and androgen receptor (AR). Our group previously identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance via interference of NCOR2 repression on ER.
Ho Tsoi, Ling Shi, Man-Hong Leung, Ellen P. S. Man, Zi-Qing So, Wing-Lok Chan, Ui-Soon Khoo   +6 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Leishmania is not prone to develop resistance to tamoxifen

International Journal for Parasitology: Drugs and Drug Resistance, 2015
Tamoxifen, an antineoplastic agent, is active in vitro and in vivo against the parasitic protozoa Leishmania. As part of our efforts to unravel this drug's mechanisms of action against the parasite and understand how resistance could arise, we tried to select tamoxifen-resistant Leishmania amazonensis.
Adriano C. Coelho, Cristiana T. Trinconi, Luisa Senra, Jenicer K.U. Yokoyama-Yasunaka, Silvia R.B. Uliana   +4 more
openaire   +3 more sources

CD63+ Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

Advanced Science, 2020
Tamoxifen remains the most effective treatment for estrogen receptor α (ERα)‐positive breast cancer. However, many patients still develop resistance to tamoxifen in association with metastatic recurrence, which presents a tremendous clinical challenge ...
Yuan Gao, Xiaoju Li, Cheng Zeng, Chenlin Liu, Qiang Hao, Weina Li, Kuo Zhang, Wangqian Zhang, Shuning Wang, Huadong Zhao, Dong Fan, Meng Li, Yingqi Zhang, Wei Zhang, Cun Zhang   +14 more
doaj   +1 more source